Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein

Forty-six monoclonal antibodies (MAbs) able to bind to the native, monomeric gp120 glycoprotein of the human immunodeficiency virus type 1 (HIV-1) LAI (HXBc2) strain were used to generate a competition matrix. The data suggest the existence of two faces of the gp120 glycoprotein. The binding sites for the viral receptor, CD4, and neutralizing MAbs appear to cluster on one face, which is presumably exposed on the assembled, oligomeric envelope glycoprotein complex. A second gp120 face, which is presumably inaccessible on the envelope glycoprotein complex, contains a number of epitopes for nonneutralizing antibodies. This analysis should be useful for understanding both the interaction of antibodies with the HIV-1 gp120 glycoprotein and neutralization of HIV-1.

[1]  N. Sullivan,et al.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 , 1993, Journal of virology.

[2]  Reed J. Harris,et al.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.

[3]  R. Garry,et al.  A general model for the surface glycoproteins of HIV and other retroviruses. , 1995, AIDS research and human retroviruses.

[4]  D. Ho,et al.  Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[6]  S. Zolla-Pazner,et al.  Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. , 1992, AIDS research and human retroviruses.

[7]  G. Shaw,et al.  Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions , 1987, Journal of virology.

[8]  E. Freed,et al.  Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120 , 1994, Journal of virology.

[9]  D. Ho,et al.  Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.

[10]  R. Compans,et al.  Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides , 1994, Journal of virology.

[11]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[12]  T. Chou,et al.  Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. , 1992, AIDS research and human retroviruses.

[13]  R. Weiss,et al.  Neutralizing monoclonal antibodies to the AIDS virus. , 1988, AIDS.

[14]  J. McKeating,et al.  Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gpl20 , 1992 .

[15]  J. Sodroski,et al.  Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. , 1992, Journal of acquired immune deficiency syndromes.

[16]  J. Sodroski,et al.  Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein , 1991, Journal of virology.

[17]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[18]  J. Moore,et al.  Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. , 1990, AIDS.

[19]  D. Ho,et al.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody , 1991, Journal of virology.

[20]  M. Schutten,et al.  Enhancement of Infectivity of a Non‐Syncytium Inducing HIV‐1 by sCD4 and by Human Antibodies that Neutralize Syncytium Inducing HIV‐1 , 1995, Scandinavian journal of immunology.

[21]  P. Earl,et al.  In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity , 1988, Journal of virology.

[22]  G. Pauli,et al.  Inhibition of viral replication by monoclonal antibodies directed against human immunodeficiency virus gp120. , 1992, The Journal of general virology.

[23]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[24]  J. Sodroski,et al.  Antigenic variation in gp120s from molecular clones of HIV-1 LAI. , 1993, AIDS research and human retroviruses.

[25]  J. Sodroski,et al.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding , 1995, Journal of virology.

[26]  J. Sodroski,et al.  Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region , 1992, Journal of virology.

[27]  E K Ross,et al.  Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120 , 1989, Journal of virology.

[28]  J. Sodroski,et al.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.

[29]  J. Sodroski,et al.  Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120 , 1994, Journal of virology.

[30]  H. Mitsuya,et al.  Designing CD4 immunoadhesins for AIDS therapy , 1989, Nature.

[31]  J. Sodroski,et al.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions , 1993, Journal of virology.

[32]  J. Moore,et al.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans , 1993, Journal of virology.

[33]  L. Stamatatos,et al.  Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability , 1993, Journal of virology.

[34]  T. H. Lee,et al.  Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120 , 1989, Journal of virology.

[35]  J. Sodroski,et al.  Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid) , 1995, Journal of virology.

[36]  J. Sodroski,et al.  Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies , 1994, Journal of virology.

[37]  H. Lyerly,et al.  Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. , 1988, AIDS research and human retroviruses.

[38]  Hans Wolf,et al.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.

[39]  J. Sodroski,et al.  Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein , 1995, Journal of virology.

[40]  A. Trkola,et al.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.

[41]  Ying Sun,et al.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates , 1995, Journal of virology.

[42]  L. Cavacini,et al.  Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. , 1993, Virology.

[43]  K. Steimer,et al.  Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. , 1991, Science.

[44]  J. Ruysschaert,et al.  Secondary structure of gp160 and gp120 envelope glycoproteins of human immunodeficiency virus type 1: a Fourier transform infrared spectroscopic study , 1993, Journal of virology.

[45]  J. Sodroski,et al.  Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1 , 1994, Journal of virology.

[46]  J. Sodroski,et al.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody , 1991, Journal of virology.

[47]  G K Lewis,et al.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop , 1993, Journal of virology.

[48]  L. Stamatatos,et al.  Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. , 1995, Virology.

[49]  J. Sodroski,et al.  Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody , 1993, Journal of virology.

[50]  G. A. Beaudry,et al.  Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. , 1993, AIDS research and human retroviruses.

[51]  Q. Sattentau,et al.  Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains , 1993, Journal of virology.

[52]  J. Sodroski,et al.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. , 1987, Science.

[53]  J. Sodroski,et al.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.

[54]  Q. Sattentau,et al.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding , 1991, The Journal of experimental medicine.

[55]  Q. Sattentau,et al.  Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding , 1993, Journal of virology.